Success Metrics

Clinical Success Rate
41.7%

Based on 5 completed trials

Completion Rate
42%(5/12)
Active Trials
0(0%)
Results Posted
80%(4 trials)
Terminated
7(54%)

Phase Distribution

Ph phase_3
6
46%
Ph phase_2
2
15%
Ph phase_1
5
38%

Phase Distribution

5

Early Stage

2

Mid Stage

6

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
5(38.5%)
Phase 2Efficacy & side effects
2(15.4%)
Phase 3Large-scale testing
6(46.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

38.5%

5 of 13 finished

Non-Completion Rate

61.5%

8 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(5)
Terminated(8)

Detailed Status

Terminated7
Completed5
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
41.7%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (38.5%)
Phase 22 (15.4%)
Phase 36 (46.2%)

Trials by Status

terminated754%
completed538%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 13
terminatedphase_3

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

NCT03194646
terminatedphase_3

A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

NCT03240523
terminatedphase_3

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

NCT03400943
terminatedphase_3

A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

NCT03476928
terminatedphase_3

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

NCT03400956
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT03194646Phase 3

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

Terminated
NCT03240523Phase 3

A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

Terminated
NCT03400943Phase 3

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

Terminated
NCT03476928Phase 3

A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding

Terminated
NCT03400956Phase 3

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

Terminated
NCT03573336Phase 2

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis

Terminated
NCT03342859Phase 1

Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned

Terminated
NCT03699176Phase 3

Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

Withdrawn
NCT03411980Phase 1

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

Completed
NCT03092999Phase 1

Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)

Completed
NCT02465814Phase 2

Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids

Completed
NCT02262663Phase 1

Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan

Completed
NCT02456129Phase 1

Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13